About
Bio
Impact Factor:
4.798 (Source: Thomson Reuters Journal Citation Reports 2015)
Journal Ranking:
28/253 Pharmacology & Pharmacy (Source: Thomson Reuters Journal Citation Reports 2015)
Circulation:
A figure is not disclosed.
Distribution:
It is available via subscription.
Aims of the Journal:
The journal evaluates molecules, signal pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and should not include clinical information on specific drugs. Expert Opinion on Therapeutic Targets is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on novel molecular targets, with the aim of providing expert opinion on the scope for future drug development and the impact on drug discovery. Editors welcome reviews covering novel disease targets at the molecular level and their implications for future drug development and original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs.
Readership:
Scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.
Manuscript Submission:
Information for contributors can be found here and here.
Other information:
There is no generic email address. The Editorial Board can be found here.
Email
email@cision.one
Website
site@cision.one
Social media
Location
United Kingdom
Frequency
upgrade
Circulation
upgrade
Sectors
Pharmaceuticals, Science
Bio
Impact Factor: 4.798 (Source: Thomson Reuters Journal Citation Reports 2015) Journal Ranking: 28/253 Pharmacology & Pharmacy (Source: Thomson Reuters Journal Citation Reports 2015) Circulation: A figure is not disclosed. Distribution: It is available via subscription. Aims of the Journal: The journal evaluates molecules, signal pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and should not include clinical information on specific drugs. Expert Opinion on Therapeutic Targets is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on novel molecular targets, with the aim of providing expert opinion on the scope for future drug development and the impact on drug discovery. Editors welcome reviews covering novel disease targets at the molecular level and their implications for future drug development and original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs. Readership: Scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D. Manuscript Submission: Information for contributors can be found here and here. Other information: There is no generic email address. The Editorial Board can be found here.
Website
Social media
Location
Frequency
Circulation
Sectors
Pharmaceuticals, Science
Most recent articles by Expert Opinion on Therapeutic Targets
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Explore outlets similar to Expert Opinion on Therapeutic Targets
-
The New York Times
The New York Times offers the latest news from around the world. It has several different editions for Eastern and national regions. In addition, the paper gets much of its content and reporting from its many bureaus. The foreign desk oversees correspondents and stringers around the world. Daily deadlines are usually between 5pm and 6pm ET. The paper does not accept artwork. The lead time for news coverage is one day to one week, the lead time for special section features is three weeks. The lead time for advertising is 30 days.
ViewAThe New YorkerCreated in 1925 as a forum to discuss current ideas and events in metropolitan America. Its editorial content is a combination of domestic and international news analysis, along with cartoons and features pertaining to contemporary American living. Regular issue features include criticism of culture, sports, the arts and fashion as well as fiction, biographical portraits, a letters section and a listing of New York's activities. Originally founded as a weekly, he magazine is now published 47 times annually, with five of these issues covering two-week spans.Audience and Readership: (as of January 2015)Total Audience (with pass-along readership) 4,476,000Age 18-34 25%Age 35-44 16%Age 45-54 16%Age 55-64 20%Age 65+ 24%Average HHI $112,394Gender - Male/Female 47%/53%Education - Graduated College+ 62%Employed - Full-Time 52%Employment - Professional or Managerial 41%Marital Status - Married 48%Lead times:Advertising : 21 days priorFeatures : 42 days priorNews : 30 days priorMedia Kit: http://www.condenast.com/brands/new-yorker/media-kitOther Information:For press inquiries, please send an e-mail to the Public Relations department at mediarequests@newyorker.comThe outlet offers RSS (Really Simple Syndication) and a digital iPad application, available Mondays.
ViewCNN OnlineInternet version of the worldwide cable news network providing live, ongoing coverage of news around the globe 24 hours a day. Regular features spotlight public affairs, news, politics, science, technology, business, food, medicine, fashion, sports, lifestyle, parenting and entertainment. The site also emphasizes topical and in-depth interviews and discussions with newsmakers, politicians, celebrities and people in the news. CNN.com has a content partnership with Health.com. Health.com stories will appear on the CNN.com website, however Health.com reporters are not employed by CNN and are better contacted through Health.com directly.
ViewNewsweekProvides a broad cross-section of readers with analysis of the major news stories of the week. Includes business, technology and consumer coverage as part of this general news. Relevant charts, maps, cartoons and photographs accompany most of the articles. Opinion columns deal with views on national and international trends in politics, the economy, personal business, the Washington scene, current affairs, lifestyles, the arts, society, health, science and technology. Newsweek was founded in 1933 by former TIME foreign editor Thomas J.C. Martyn. It was later purchased in 1961 by The Washington Post Company, who in turn sold the publication to businessman Sidney Harman in 2010. Later that year, Newsweek merged operations with Tina Brown's The Daily Beast forming the short-lived Newsweek Daily Beast Company (or NewsBeast for short). In 2012 it was announced that the magazine would assume an all-digital format in 2013 and re-brand as Newsweek Global, with the December 31 edition being its last in print. Acquired by its current owner IBT Media in 2013, the print edition was resurrected in March 2014.
ViewUse CisionOne to find more relevant outletsContact Expert Opinion on Therapeutic Targets and get access to over 850K accurate, up-to-date media profiles.
Discover the stories that impact your brand. In realtime.
CisionOne delivers relevant news, trends and conversations that matter to your brand with the world’s most comprehensive media monitoring service across Print, Online, TV, Radio, Social, Magazines, Podcasts and more.